Brilinta Taiwan Post Approval Safety Study

PHASE4CompletedINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

April 23, 2015

Primary Completion Date

February 9, 2017

Study Completion Date

February 9, 2017

Conditions
Non ST-elevation Myocardial Infarction
Interventions
DRUG

Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)

Trial Locations (13)

104

Research Site, Taipei

300

Research Site, Hsinchu

704

Research Site, Tainan City

833

Research Site, Niao-Song-Shiang

11101

Research Site, Taipei

11217

Research Site, Taipei

11220

Research Site, Taipei

22060

Research Site, Taipei

50006

Research Site, Changhua

80756

Research Site, Kaohsiung City

81362

Research Site, Kaohsiung City

Unknown

Research Site, Taichung

Research Site, Tainan County

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY